Is MGM-15 a Full Agonist?

Is MGM-15 a Full Agonist?

MGM-15 (dihydro-7-hydroxymitragynine) is a semi-synthetic derivative of kratom alkaloids that interacts with opioid receptors, particularly the mu-opioid receptor system. Within pharmacology, the key classification question is whether MGM-15 produces maximal receptor activation (full agonism) or a limited efficacy response (partial agonism). Current evidence positions MGM-15 as an opioid receptor agonist with partial agonist characteristics, rather than a confirmed full agonist, which has important implications for its potency, safety profile, and receptor signaling behavior. If you prefer a powder format, browse MGM-15 powders.

Is MGM-15 a Full Agonist?

MGM-15, also called dihydro-7-hydroxy mitragynine, is best described as an opioid receptor agonist, but available public pharmacology does not clearly establish it as a full agonist. If you prefer a tablet format, browse MGM-15 tablets.

The most cautious answer is: MGM-15 is reported as a partial agonist at the mu-opioid receptor, while also showing activity at mu and delta opioid receptors. CFSRE’s 2025 NPS Discovery monograph specifically describes MGM-15 as a partial agonist of the mu-opioid receptor. For another safety read, see Is MGM-15 Stronger than 7oh?.

TL;DR

  • MGM-15 is not confirmed as a full agonist based on current pharmacological data
  • It is best classified as a partial mu-opioid receptor agonist
  • Derived from 7-hydroxymitragynine, a key active kratom alkaloid
  • Shows activity at mu and delta opioid receptors, but with limited maximal efficacy
  • Classification impacts effects and risk profile, especially compared to full opioid agonists

What MGM-15 Is

MGM-15 is a semi-synthetic derivative of 7-hydroxymitragynine, a kratom-related alkaloid. It is structurally related to mitragynine, 7-hydroxymitragynine, and MGM-16. MGM-15 was developed in research involving opioid receptor ligands derived from mitragynine-related scaffolds.

Full Agonist vs Partial Agonist

A full agonist activates a receptor to its maximum possible signaling response in a given assay.

A partial agonist binds and activates the receptor, but produces a lower maximum response than a full agonist, even when receptor occupancy is high.

For MGM-15, the available public evidence supports opioid agonist activity, especially at mu-opioid receptor and delta-opioid receptor systems, but does not support confidently calling it a full agonist.

Why the Confusion Exists

MGM-15 is often discussed alongside MGM-16, which was described as a potent μ/δ dual opioid agonist and showed higher potency than MGM-15 in research models. This can cause MGM-15 to be grouped broadly as an “opioid agonist,” even though “agonist” does not automatically mean “full agonist.”

FAQ

Is MGM-15 a full agonist at the mu-opioid receptor?

Current pharmacological evidence does not classify MGM-15 as a full agonist. It is more accurately described as a partial agonist, meaning it activates the mu-opioid receptor but does not produce the maximum possible biological response even at higher concentrations.

What receptors does MGM-15 interact with?

MGM-15 primarily interacts with mu-opioid receptors and also shows activity at delta-opioid receptors. These receptor interactions place it within the broader category of opioid receptor ligands derived from kratom-related compounds.

How does MGM-15 differ from a full opioid agonist?

A full agonist (such as morphine) produces maximal receptor activation, while MGM-15 produces submaximal activation. This difference affects signaling strength, physiological response, and potentially safety characteristics such as respiratory depression risk.

Is MGM-15 stronger than 7-hydroxymitragynine?

MGM-15 is structurally derived from 7-hydroxymitragynine, but “strength” depends on how it is measured (binding affinity, efficacy, or in vivo effects). Available data suggests MGM-15 has modified potency and efficacy, not necessarily higher maximal effect.

Why is MGM-15 often confused with full agonists?

MGM-15 is frequently grouped under “opioid agonists,” which can lead to oversimplification. The term “agonist” includes both full and partial agonists, and without specifying efficacy, the distinction is often lost in summaries and secondary sources.